RECRUITING

Belatacept in Heart Transplantation

Conditions

Heart Transplant Transplantation Standard of care Belatacept Tacrolimus

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a belatacept-based regimen with gradual tacrolimus withdrawal over 9-months post-transplant. Both study arms will receive CellCept® (mycophenolate mofetil- MMF) or Myfortic® (mycophenolate sodium). Corticosteroids will be continued throughout the study in the belatacept arm. The primary objective is to evaluate whether NULOJIX® (belatacept), when implemented with gradual tacrolimus withdrawal over 9 months, is safe with respect to preventing the composite endpoint of acute cellular rejection (ACR) \>= International Society of Heart and Lung Transplantation (ISHLT) 2R, hemodynamic compromise rejection in the absence of a biopsy or histological rejection, re-transplantation, and death at 18 months post-transplant.

Official Title

Belatacept With Delayed Tacrolimus Withdrawal Versus Standard-of-Care Tacrolimus in Heart Transplant Recipients (RTB-013)

Quick Facts

Study Start:2024-11-18

Study Completion:2028-01-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06478017

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 71 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subject must be able to understand the purpose of the study and be willing to participate and provide written consent 2. Recipient of a primary heart transplant (heart transplant only) 3. Epstein-Barr Virus (EBV) seropositive 4. Agreement to use contraception; according to the Food and Drug Administration (FDA) Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study 5. In the absence of a contraindication, vaccinations must be up to date per the Division of Allergy, Immunology, and Transplantation (DAIT) Vaccination Guidance for Patients in Transplant Trials (Refer to the Manual of Procedures) 6. Mechanical support or investigational drug trials where the intervention ends at the time of transplantation are permitted. 1. Recipient of a primary heart transplant 2. No desensitization therapy prior to transplant 3. Negative crossmatch actual or virtual, on the most recent sera as determined by the participating study center 4. Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) prior to randomization 5. Agreement to use contraception; according to the FDA Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug 6. Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration equation (CKD-epi)) \>30ml/min/1.73m\^2 and \<100ml/min/1.73m\^2	1. Candidate for multiple solid organ or tissue transplants 2. Prior history of any organ, tissue, or cellular transplant 3. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period 4. History of severe allergic and/or anaphylactic reactions to humanized or murine monoclonal antibodies 5. Known hypersensitivity to NULOIX (belatacept) or ORENCIA (Abatacept) 6. Previous treatment with NULOIX (belatacept) or ORENCIA (Abatacept) 7. Epstein Barr Virus (EBV) seronegative or indeterminant 8. Human Immunodeficiency Virus (HIV) positive 9. Hepatitis B surface antigen positive 10. Hepatitis B core antibody positive 11. Hepatitis C virus antibody (HCV Ab+) and hepatitis C virus (HCV) Polymerase Chain Reaction (PCR) positive patients 12. Patients with a previous history of active Tuberculosis (TB) 13. Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must have completed appropriate therapy for LTBI (https://www.cdc.gov/tb/topic/treatment/ltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant 14. Positive serology for T. cruzi or known/suspected history of Chagas disease 15. Findings on pre-transplant or pre-randomization chest x-ray suggestive of fungal infection. 16. Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections 17. White blood cell (WBC) count \<3.0 or an absolute neutrophil count (ANC) of less than 1500 cells/mm3 on \>=2 occasions at any time prior to enrollment 18. History of central nervous system (CNS) infection 19. History of active inflammatory bowel disease, chronic diarrhea, or malabsorption 20. History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate 21. History of AL amyloidosis 22. Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri- transplant period 23. Patients who i) have undergone desensitization, ii) are undergoing or are planned to undergo desensitization, or iii) are intended to receive therapeutic interventions that are used for the purpose of desensitization prior to transplant 24. Pretransplant Calculated Panel Reactive Antibody (cPRA) calculated by Single Antigen Bead (SAB) testing \> 25% 25. The use of immunosuppressive biologics within 3 months prior to transplant is not permitted. Non- immunosuppressive biologics such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors must be stopped at the time of transplant 26. Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period 27. The intended use of high dose (\>= 2g/kg) intravenous immunoglobulin before or at the time of transplant or before study drug administration 28. A personal history of severe hypogammaglobulinemia (\<300mg/dL) 29. Intent to give the patient a live vaccine within 30 days prior to randomization 30. Use or intended use of other investigational drugs after transplant 31. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the potential participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study 1. Recipient of multiple solid organ or tissue transplants 2. Prior history of any organ, tissue, or cellular transplant 3. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period 4. History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies 5. Known hypersensitivity to Belatacept (NULOJIX) or Abatacept (ORENCIA) 6. Previous treatment with Belatacept (NULOJIX) or Abatacept (ORENCIA) 7. Epstein Barr Virus (EBV) seronegative or indeterminant 8. HIV positive patient 9. Hepatitis B surface antigen positive patient 10. Hepatitis B core antibody positive patient 11. Hepatitis B negative transplant recipient that received a transplant from a Hepatitis B core antibody positive donor 12. Hepatitis C virus antibody (HCV Ab+) and HCV PCR positive patients 13. Recipient of allograft from a hepatitis C virus nucleic acid test (NAT) positive donor 14. Patients with a previous history of active Tuberculosis (TB) 15. Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must complete appropriate therapy for LTBI (https://www.cdc.gov/tb/topic/treatment/ltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant 16. Positive serology for T. cruzi or known/suspected history of Chagas disease 17. Findings on pre-transplant or pre-randomization chest x-ray suggestive of fungal infection. 18. Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections 19. White blood cell (WBC) count \<3.0 or an absolute neutrophil count (ANC) of less than 1500 cells/mm3 on \>=2 occasions at any time prior to randomization 20. CMV high risk mismatch (D+/R-) 21. History of central nervous system (CNS) infection 22. History of active inflammatory bowel disease, chronic diarrhea, or malabsorption 23. History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate 24. History of AL amyloidosis 25. Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri- transplant period 26. Patients who have undergone desensitization or received therapeutic interventions that are used for the purpose of desensitization prior to transplant 27. cPRA calculated by Single Antigen Bead (SAB) testing \> 25% at the time of transplant or any donor specific antibodies before or at the time of transplant (local lab) 28. Patients who have been treated with immunosuppressive biologics within 3 months prior to transplant (non-immunosuppressive biologics must have been stopped at the time of transplant) 29. Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period 30. Patients who are administered or intended to be administered high dose (\>=2g/kg) intravenous immunoglobulin in the immediate post-transplant period 31. A personal history of severe hypogammaglobulinemia (\<300mg/dL) 32. Receipt of a live vaccine within 30 days prior to randomization 33. Intent to use any other investigational drugs after transplantation 34. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study

Inclusion Criteria

Exclusion Criteria

1. Subject must be able to understand the purpose of the study and be willing to participate and provide written consent
2. Recipient of a primary heart transplant (heart transplant only)
3. Epstein-Barr Virus (EBV) seropositive
4. Agreement to use contraception; according to the Food and Drug Administration (FDA) Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study
5. In the absence of a contraindication, vaccinations must be up to date per the Division of Allergy, Immunology, and Transplantation (DAIT) Vaccination Guidance for Patients in Transplant Trials (Refer to the Manual of Procedures)
6. Mechanical support or investigational drug trials where the intervention ends at the time of transplantation are permitted.
1. Recipient of a primary heart transplant
2. No desensitization therapy prior to transplant
3. Negative crossmatch actual or virtual, on the most recent sera as determined by the participating study center
4. Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) prior to randomization
5. Agreement to use contraception; according to the FDA Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug
6. Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease Epidemiology Collaboration equation (CKD-epi)) \>30ml/min/1.73m\^2 and \<100ml/min/1.73m\^2

1. Candidate for multiple solid organ or tissue transplants
2. Prior history of any organ, tissue, or cellular transplant
3. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period
4. History of severe allergic and/or anaphylactic reactions to humanized or murine monoclonal antibodies
5. Known hypersensitivity to NULOIX (belatacept) or ORENCIA (Abatacept)
6. Previous treatment with NULOIX (belatacept) or ORENCIA (Abatacept)
7. Epstein Barr Virus (EBV) seronegative or indeterminant
8. Human Immunodeficiency Virus (HIV) positive
9. Hepatitis B surface antigen positive
10. Hepatitis B core antibody positive
11. Hepatitis C virus antibody (HCV Ab+) and hepatitis C virus (HCV) Polymerase Chain Reaction (PCR) positive patients
12. Patients with a previous history of active Tuberculosis (TB)
13. Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must have completed appropriate therapy for LTBI (https://www.cdc.gov/tb/topic/treatment/ltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant
14. Positive serology for T. cruzi or known/suspected history of Chagas disease
15. Findings on pre-transplant or pre-randomization chest x-ray suggestive of fungal infection.
16. Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections
17. White blood cell (WBC) count \<3.0 or an absolute neutrophil count (ANC) of less than 1500 cells/mm3 on \>=2 occasions at any time prior to enrollment
18. History of central nervous system (CNS) infection
19. History of active inflammatory bowel disease, chronic diarrhea, or malabsorption
20. History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate
21. History of AL amyloidosis
22. Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri- transplant period
23. Patients who i) have undergone desensitization, ii) are undergoing or are planned to undergo desensitization, or iii) are intended to receive therapeutic interventions that are used for the purpose of desensitization prior to transplant
24. Pretransplant Calculated Panel Reactive Antibody (cPRA) calculated by Single Antigen Bead (SAB) testing \> 25%
25. The use of immunosuppressive biologics within 3 months prior to transplant is not permitted. Non- immunosuppressive biologics such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors must be stopped at the time of transplant
26. Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period
27. The intended use of high dose (\>= 2g/kg) intravenous immunoglobulin before or at the time of transplant or before study drug administration
28. A personal history of severe hypogammaglobulinemia (\<300mg/dL)
29. Intent to give the patient a live vaccine within 30 days prior to randomization
30. Use or intended use of other investigational drugs after transplant
31. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the potential participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
1. Recipient of multiple solid organ or tissue transplants
2. Prior history of any organ, tissue, or cellular transplant
3. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period
4. History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies
5. Known hypersensitivity to Belatacept (NULOJIX) or Abatacept (ORENCIA)
6. Previous treatment with Belatacept (NULOJIX) or Abatacept (ORENCIA)
7. Epstein Barr Virus (EBV) seronegative or indeterminant
8. HIV positive patient
9. Hepatitis B surface antigen positive patient
10. Hepatitis B core antibody positive patient
11. Hepatitis B negative transplant recipient that received a transplant from a Hepatitis B core antibody positive donor
12. Hepatitis C virus antibody (HCV Ab+) and HCV PCR positive patients
13. Recipient of allograft from a hepatitis C virus nucleic acid test (NAT) positive donor
14. Patients with a previous history of active Tuberculosis (TB)
15. Subjects must be tested for latent TB infection (LTBI) within a year prior to transplant. Testing should be conducted using either a PPD or Interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB). Patients with a positive test for latent TB infection (LTBI) must complete appropriate therapy for LTBI (https://www.cdc.gov/tb/topic/treatment/ltbi.htm). A subject is considered eligible only if they have a negative test for LTBI within one year prior to transplant OR if they have completed appropriate LTBI therapy within one year prior to transplant
16. Positive serology for T. cruzi or known/suspected history of Chagas disease
17. Findings on pre-transplant or pre-randomization chest x-ray suggestive of fungal infection.
18. Known active current viral, fungal, mycobacterial or other infections (including, but not limited to atypical mycobacterial disease and herpes zoster), not including drive line infections
19. White blood cell (WBC) count \<3.0 or an absolute neutrophil count (ANC) of less than 1500 cells/mm3 on \>=2 occasions at any time prior to randomization
20. CMV high risk mismatch (D+/R-)
21. History of central nervous system (CNS) infection
22. History of active inflammatory bowel disease, chronic diarrhea, or malabsorption
23. History of malignancy, per discretion of oncology consult and study oversight team, will be permitted to participate
24. History of AL amyloidosis
25. Patients who are administered or intended to be administered induction therapy (cytolytic agents such as anti-thymocyte globulin or anti-IL2R therapies such as basiliximab) in the immediate peri- transplant period
26. Patients who have undergone desensitization or received therapeutic interventions that are used for the purpose of desensitization prior to transplant
27. cPRA calculated by Single Antigen Bead (SAB) testing \> 25% at the time of transplant or any donor specific antibodies before or at the time of transplant (local lab)
28. Patients who have been treated with immunosuppressive biologics within 3 months prior to transplant (non-immunosuppressive biologics must have been stopped at the time of transplant)
29. Patients for whom there is an intent to administer biologics other than those indicated by protocol during the study period
30. Patients who are administered or intended to be administered high dose (\>=2g/kg) intravenous immunoglobulin in the immediate post-transplant period
31. A personal history of severe hypogammaglobulinemia (\<300mg/dL)
32. Receipt of a live vaccine within 30 days prior to randomization
33. Intent to use any other investigational drugs after transplantation
34. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study

Contacts and Locations

Study Contact

Yvonne Morrison

CONTACT

301-706-9137

ymorrison@niaid.nih.gov

Jaclyn Evans

CONTACT

240-669-5470

Jaclyn.evans@nih.gov

Principal Investigator

Joren C Madsen, MD, DPhil

STUDY_CHAIR

Massachusetts General Hospital

Jon A. Kobashigawa, MD

STUDY_CHAIR

Cedars-Sinai Medical Center

Marlena Habal, MD

PRINCIPAL_INVESTIGATOR

NYU Grossman School of Medicine

Christian P. Larsen, MD, DPhil

STUDY_CHAIR

Emory University

Study Locations (Sites)

Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146)

Los Angeles, California, 90048

United States

Tampa General Hospital (Site # 71150)

Tampa, Florida, 33606

United States

NYU Langone Health (Site # 71177)

New York, New York, 10016

United States

University of Utah Medical Center (Site # 71126)

Salt Lake City, Utah, 84132

United States

Collaborators and Investigators

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Joren C Madsen, MD, DPhil, STUDY_CHAIR, Massachusetts General Hospital
Jon A. Kobashigawa, MD, STUDY_CHAIR, Cedars-Sinai Medical Center
Marlena Habal, MD, PRINCIPAL_INVESTIGATOR, NYU Grossman School of Medicine
Christian P. Larsen, MD, DPhil, STUDY_CHAIR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-18

Study Completion Date2028-01-31

Study Record Updates

Study Start Date2024-11-18

Study Completion Date2028-01-31

Terms related to this study

Keywords Provided by Researchers

Heart transplant
Transplantation
Standard of care
Belatacept
Tacrolimus

Additional Relevant MeSH Terms

Heart Transplant